Subscribe
shutterstock_1857404794_michael_vi
Michael Vi / Shutterstock.com
9 May 2022AsiaAlex Baldwin

BGI wins $333m in DNA patent suit with Illumina

Illumina has been ordered to pay more than $333 million to Chinese sequencing company MGI—a subsidiary of BGI Group formally known as Complete Genomics—following a jury ruling that Illumina infringed two of its DNA-sequencing patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.
Big Pharma
Scientist accuses Illumina of long-running trade secrets plot
11 April 2023   Dispute stems from the theft of a data set of ZipCode sequences used in genetic testing | Plaintiff holds that pharma companies conspired against him | Cornell University claimed Thermo Fisher had misled it into settling a lawsuit in 2017.
Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.
Big Pharma
Scientist accuses Illumina of long-running trade secrets plot
11 April 2023   Dispute stems from the theft of a data set of ZipCode sequences used in genetic testing | Plaintiff holds that pharma companies conspired against him | Cornell University claimed Thermo Fisher had misled it into settling a lawsuit in 2017.
Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

More on this story

Big Pharma
Illumina fined record €432m for completing Grail merger before EC approval
13 July 2023   Commission says dealmakers ‘knowingly and intentionally’ breached standstill obligation | Grail receives the first-ever fine for a target company under EU merger rules.
Big Pharma
Scientist accuses Illumina of long-running trade secrets plot
11 April 2023   Dispute stems from the theft of a data set of ZipCode sequences used in genetic testing | Plaintiff holds that pharma companies conspired against him | Cornell University claimed Thermo Fisher had misled it into settling a lawsuit in 2017.
Big Pharma
EU blocks $7.1bn takeover of cancer detection company
8 September 2022   Illumina bid would have “stifled innovation” | EU said Illumina was the "unrivalled supplier” of next-generation sequencing systems for genetic and genomic analysis.

More features

Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
HLK adds CRISPR specialist as partner
UPC delivers first 'imminent infringement' decision in biosimilar dispute